查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844100

腦腫瘤診斷市場按技術、產品、適應症、通路和最終用戶分類－2025-2032年全球預測

Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦腫瘤診斷市場規模將達到 118.4 億美元，複合年成長率為 12.80%。

主要市場統計數據
基準年 2024 45.2億美元
預計年份：2025年 51.1億美元
預測年份：2032年 118.4億美元
複合年成長率 (%) 12.80%

對影響腦腫瘤診斷當前及近期未來的臨床需求、診斷路徑和監管促進因素進行全面分析

本執行摘要重點在於當代腦腫瘤診斷生態系統，著重闡述影響診斷實踐的臨床需求、技術發展軌跡和相關人員的獎勵。摘要首先概述了從症狀出現到組織病理學確診的診斷流程，重點強調了診斷準確性、週轉時間和可及性如何影響患者預後。摘要還概述了先進影像技術、分子檢測和傳統病理工作流程之間的相互作用，以及這些診斷方式如何整合到多學科診療流程中。

引言也指出，監管的清晰度和基於價值的報銷模式往往決定著一項創新能否從研究階段走向常規臨床應用，因此，監管考慮和研究動態是推動或阻礙技術採納的重要因素。最後，引言為本概述的其餘部分設定了預期：對變革性轉變的評估、關稅的影響、競爭考察、區域動態、競爭定位，以及為臨床醫生、診斷服務提供者和投資者提供策略指南的實用建議。

影像學、分子診斷和數位病理學領域的創新如何重新定義腦瘤診斷流程、數據整合和臨床決策

腦腫瘤診斷正經歷變革時期，主要得益於影像學、分子分析和數位病理學的融合。磁振造影通訊協定和混合成像技術的進步，使得病灶特徵的表徵更加精細，並能更可靠地區分腫瘤分級和治療相關變化。同時，次世代定序和標靶PCR技術拓展了可用於診斷和治療選擇的分子特徵，從而增強了精準診斷在治療方案製定中的作用。

這些技術發展伴隨著臨床工作流程的演變，後者優先考慮微創取樣和長期監測。液態切片方法和更精準的影像導引切片檢查標靶技術降低了手術風險，同時提高了病人歷程可獲取的分子數據的頻率和豐富度。此外，人工智慧和機器學習正被應用於擴展影像解讀和組織病理學審查，從而實現更快的診斷並降低觀察者間的差異。這些轉變並非漸進式的；它們正在重塑多學科診療團隊、數據管治模式以及供應商與醫療機構之間的夥伴關係，促使醫療機構重新評估其診斷平台以及耗材和資訊技術方面的資金投入。

評估2025年關稅和貿易調整如何重塑腦腫瘤診斷供應鏈的籌資策略、供應商多元化和成本控制。

2025年關稅調整和貿易政策調整的累積影響，對供應鏈和成本帶來了多重壓力，供應商和製造商必須積極應對。進口設備零件、試劑和影像處理硬體關稅的提高，正在改變診斷實​​驗室和醫院的採購策略，迫使各機構探索替代籌資策略、重新談判供應商契約，並建立本地化的庫存緩衝，以維持臨床服務的連續性。

這些不利因素也加速了關於供應商多元化以及關鍵試劑和影像耗材近岸外包的討論。診斷服務提供者正在權衡短期價格上漲與長期供應穩定性的益處，通常選擇投資於維護和培訓服務，以延長設備的使用壽命。同時，一些製造商正在透過調整產品系列和包裝來應對，以減輕關稅的影響，或加強與監管機構和支付方利益相關人員的溝通，以證明其臨床價值提案，從而獲得更高的報銷，抵消增加的營運成本。因此，籌資策略、合約靈活性和營運應急計畫在市場上的重要性正變得與臨床差異化同等重要。

多維度的細分觀點揭示了技術類型、產品類型、臨床適應症、分銷管道和最終用戶如何影響技術採納和臨床影響。

深入的市場細分闡明了技術、產品組合、臨床適應症、分銷管道和終端用戶畫像如何共同決定產品需求和市場接受度。 CT、MRI 和 PET 等影像學技術可提供結構和功能方面的資訊，指南手術方案製定並監測治療反應。分子診斷技術，包括次世代定序和 PCR 方法，可提供基因組和轉錄組資訊，並為標靶治療和臨床試驗註冊提供依據。

從產品類型角度來看，耗材和試劑（包括套件和探針）是分子檢測通量的主要來源，而診斷系統、成像系統和檢測設備則構成決定檢測能力和通量的基礎設施。設備維護、培訓和技術支援等服務對於維持診斷品質和運作至關重要。就臨床適應症而言，不同腫瘤類型的診斷需求各不相同，包括星狀細胞瘤、多形性膠質母細胞瘤、腦膜瘤和寡樹突膠質瘤。多形性膠質母細胞瘤病例通常需要快速的多模態診斷以製定積極的治療方案，而腦膜瘤的評估通常依賴影像學特徵和手術病理。分銷管道動態表明，線下關係對於複雜的安裝和臨床醫生參與仍然至關重要，而線上管道在耗材採購和資訊傳播方面的影響力日益增強。診斷實驗室優先考慮通量、驗證和合規性；醫院優先考慮整合工作流程和多學科協作；而研發部門則優先考慮分析靈活性和檢測方法開發能力。了解這些細分市場如何相互作用，有助於明確創新投資和商業性努力可以在哪些方面帶來最強勁的臨床和經濟回報。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和基礎設施存在差異，這些差異會影響診斷應用管道和策略重點。

區域動態是我們策略的核心，因為美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、法規環境和醫療基礎設施存在顯著差異。美洲的醫療體系往往以高度先進的三級醫療中心為特徵，這些中心擁有完善的報銷機制和龐大的研究網路，並且擴大採用尖端影像和分子診斷技術。這使得創新成果能夠迅速轉化為臨床應用，但也對具有明確臨床效用的差異化診斷技術提出了更高的競爭要求。

在歐洲、中東和非洲，分散的法律規範和差異化的報銷環境往往促使供應商採取針對特定國家的策略，與當地經銷商和學術中心合作，以檢驗臨床和經濟價值。同時，亞太地區既有快速發展的都市區醫療體系，也有資源匱乏的環境。主要市場的大型教學醫院和研究機構推動了新一代定序（NGS）和先進影像技術的應用，而中東和非洲其他地區則優先考慮經濟高效、可擴展的診斷方法和穩健的供應鏈解決方案。在這些全部區域，當地臨床實踐、基礎設施準備和商業模式的相互作用，將決定製造商應優先投資於哪些方面的培訓、服務網路和循證實踐，以支持技術的推廣應用。

競爭動態揭示了現有企業、分子專家和敏捷創新者如何透過夥伴關係、證據和服務產品來定位自身。

腦腫瘤診斷領域的競爭格局呈現出多元化的特點，既有成熟的影像和實驗室設備製造商，也有專注於分子診斷的專業公司，以及致力於人工智慧輔助解讀和新型檢測技術的新興企業。現有影像設備供應商透過配套服務協議和長期維護合約與醫院和神經外科中心保持緊密的合作關係，這導致轉換成本高昂，但也為在混合影像和工作流程整合方面開展合作創造了機會。分子診斷公司則透過檢測範圍廣、檢測靈敏度高以及針對臨床終點的驗證來脫穎而出，並經常與學術中心合作進行前瞻性評估和指南整合。

規模較小的創新者憑藉單項分析物檢測或增強放射學和病理學解讀的人工智慧演算法，開闢了利基市場，並經常尋求與大型製造商達成合作開發或許可協議以擴大銷售。那些產品與臨床醫生工作流程相契合、提供可靠的真實世界證據並透過培訓和服務支持實施的公司，更有可能確保產品的持續應用。策略聯盟、技術授權和有針對性的收購仍然是市場參與企業擴展自身能力和地理覆蓋範圍的主要途徑。

為產業領導者提供可操作的策略重點，以協調產品創新、供應鏈韌性、證據產生和臨床應用這四項重要任務。

這意味著要投資於整合影像、分子數據和病理學的綜合診斷解決方案；透過策略採購和服務模式增強供應鏈韌性；並建立健全的證據生成機制，以證明其臨床效用和經濟價值。優先採用綜合解決方案可以減少臨床工作流程中的摩擦，並促進與醫療服務提供者建立更深的聯繫。對維護、培訓和遠端支援的投資也有助於降低停機風險，並提高客戶維繫。

同時，企業應採用靈活的商業模式，既適應集中式實驗室工作流程，也適應就地檢驗模式，並逐步滲透到醫院系統和專科診斷實驗室。證據的產生需要前瞻性臨床檢驗和衛生經濟學分析，這些分析必須能夠引起支付方和醫院採購委員會的共鳴。最後，與學術中心和患者權益組織建立夥伴關係，將加快獲得檢驗臨床隊列，從而提高指南採納和臨床醫生認可的可能性。

一項嚴謹的混合方法研究途徑將結合一手研究（包括臨床醫生訪談）和二手文獻，以檢驗診斷性能和實施方面的見解。

該分析整合了對臨床專家、實驗室主任和行業高管的訪談以及二手研究，包括同行評審文獻、監管出版物和技術白皮書。定性訪談深入分析了臨床工作流程、診斷路徑中的痛點以及醫院和診斷實驗室面臨的實際限制。二級資訊來源用於驗證技術能力、監管里程碑和公共部門採購趨勢，特別關注近期同行評審的、檢驗診斷性能指標和實施結果的研究。

我們採用多層檢驗流程加強資料完整性，包括將技術屬性與製造商的技術規格進行交叉檢驗，並諮詢獨立的臨床病理學家。我們記錄了經驗證據仍然匱乏的領域，例如跨地區和跨機構類型的抽樣，以及某些新興液態切片方法的臨床效用，從而解決了局限性和潛在偏差。在可行的情況下，我們優先考慮可重複的臨床觀察和經驗豐富的從業者的共識觀點，以確保我們的分析具有實用性和與臨床實際情況的相關性。

本概要簡要介紹了將診斷技術進步轉化為改善患者預後所需的技術、證據和營運策略的整合。

總之，腦腫瘤診斷領域正朝著整合的、數據豐富的診斷生態系統轉型，該系統融合了先進的影像技術、分子譜分析和最佳化的病理工作流程。這一發展方向為提高診斷準確性和實現個體化治療方案提供了巨大機遇，但要充分發揮其潛力，需要在技術整合、臨床醫生培訓和循證醫學證據生成方面進行協調一致的投資。同時，不斷變化的貿易動態以及監管和報銷環境的區域差異，也要求制定適應性強的商業策略和建構具有韌性的供應鏈。

因此，決策者應著重於實現不同模式間的互通性，以令人信服的真實世界證據支持臨床應用，並設計靈活的交付模式以滿足不同醫療機構的需求。將技術創新與切實可行的應用管道和相關人員的參與相結合，可以加速診斷技術的進步轉化為患者療效的改善，同時保持營運和財務的永續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用新一代定序技術進行個人化腦腫瘤分子譜分析
  • 將人工智慧演算法整合到 MRI 分析中以提高診斷準確性
  • 開發液態生物檢體檢測方法，用於非侵入性檢測神經膠母細胞瘤的復發和進展。
  • 用於同時檢測神經蛋白生物標記的多重免疫檢測盒的出現
  • 拓展遠端醫療平台，促進遠距神經影像和跨學科協作
  • PET追蹤劑在標靶腫瘤代謝、用於腦腫瘤早期檢測和監測的進展
  • 監管部門的核准推動了照護現場膠質瘤診斷設備在臨床環境中的商業化。
  • 整合精準醫學影像、基因體學和蛋白質體學資料的綜合診斷平台發展迅速
  • 製藥公司和診斷公司合作開發腦瘤伴隨檢測
  • 新興市場對經濟高效的篩檢解決方案的需求日益成長，以提高腦腫瘤的早期檢測率

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 腦腫瘤診斷市場（依技術分類）

  • 基因檢測
  • 影像
    • 電腦斷層掃描
    • MRI
    • PET
  • 分子診斷
    • NGS
    • PCR
  • 病理
    • 切片檢查分析
    • 組織病理學

第9章 腦腫瘤診斷產品市場

  • 耗材和試劑
    • 套件
    • 探針和試劑
  • 裝置
    • 診斷系統
    • 影像系統
    • 實驗室設備
  • 服務
    • 維護
    • 培訓和支持

第10章 腦腫瘤診斷市場（依適應症分類）

  • 星狀細胞瘤
  • 多形性膠質母細胞瘤
  • 腦膜瘤
  • 寡樹突膠質瘤

第11章 腦腫瘤診斷市場（依通路分類）

  • 離線
  • 線上

第12章 腦腫瘤診斷市場（依最終用戶分類）

  • 診斷實驗室
  • 醫院
  • 研究所

第13章 腦腫瘤診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腦腫瘤診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國腦瘤診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • General Electric Company
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Illumina, Inc.
    • Abbott Laboratories
    • Agilent Technologies, Inc.
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market is projected to grow by USD 11.84 billion at a CAGR of 12.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.52 billion
Estimated Year [2025] USD 5.11 billion
Forecast Year [2032] USD 11.84 billion
CAGR (%) 12.80%

Comprehensive situational framing of clinical imperatives, diagnostic pathways, and regulatory drivers shaping the present and near-term future of brain cancer diagnostics

This executive summary introduces a focused analysis of the contemporary brain cancer diagnostics ecosystem, emphasizing clinical needs, technological trajectories, and stakeholder incentives that are shaping diagnostic practice. The narrative begins by framing the diagnostic journey from symptom presentation through to histopathological confirmation, highlighting where diagnostic accuracy, turnaround time, and accessibility intersect to influence patient outcomes. It outlines the interplay between advanced imaging modalities, molecular assays, and traditional pathology workflows, and how these modalities are being integrated into multi-disciplinary care pathways.

The introduction also situates regulatory considerations and reimbursement dynamics as critical enablers or impediments to adoption, noting that regulatory clarity and value-based reimbursement models frequently determine whether innovations transition from research settings into routine clinical use. Finally, the introduction sets expectations for the remainder of the summary: an assessment of transformative shifts, tariff impacts, segmentation insights, regional dynamics, competitive positioning, and practical recommendations to guide strategy for clinicians, diagnostics providers, and investors.

How converging imaging, molecular diagnostics, and digital pathology innovations are redefining diagnostic workflows, data integration, and clinical decision-making for brain tumors

The diagnostic landscape for brain tumors is undergoing a transformative shift driven by convergence across imaging, molecular analysis, and digital pathology. Advances in magnetic resonance imaging protocols and hybrid imaging techniques are refining lesion characterization, enabling more confident distinctions between tumor grades and treatment-related changes. Concurrently, next-generation sequencing and targeted PCR panels are expanding the molecular fingerprints available for diagnosis and therapeutic selection, thereby elevating the role of precision diagnostics in care planning.

These technological developments are accompanied by evolving clinical workflows that prioritize minimally invasive sampling and longitudinal monitoring. Liquid biopsy approaches and improved biopsy targeting through image guidance are reducing procedural risk while increasing the frequency and richness of molecular data available across the patient journey. Moreover, artificial intelligence and machine learning are being deployed to augment image interpretation and histopathology review, accelerating diagnostic turnaround and reducing inter-observer variability. Collectively, these shifts are not merely incremental; they are reconfiguring multidisciplinary care teams, data governance models, and vendor-provider partnerships, and are prompting institutions to reassess capital allocation for diagnostic platforms versus consumables and informatics.

Assessing how 2025 tariff and trade adjustments are reshaping procurement strategies, supplier diversification, and cost management across brain cancer diagnostic supply chains

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced a layer of supply chain and cost pressure that providers and manufacturers must actively manage. Increased duties on imported instrumentation components, reagents, and imaging hardware have altered procurement calculus for diagnostic laboratories and hospitals, leading organizations to explore alternative sourcing strategies, renegotiated supplier contracts, and localized inventory buffers to preserve clinical continuity.

These trade headwinds have also accelerated discussions around supplier diversification and nearshoring for critical reagents and imaging consumables. Diagnostic providers are balancing the short-term implications of higher landed costs against the long-term benefits of supply resilience, often choosing to invest in maintenance and training services to extend equipment lifecycle performance. At the same time, some manufacturers have reacted by adjusting product portfolios and packaging to mitigate tariff exposure, or by increasing engagement with regulatory authorities and payer stakeholders to demonstrate clinical value propositions that justify higher reimbursement to offset increased operational expense. The net result is a marketplace where procurement strategies, contracting agility, and operational contingency planning have become as important as clinical differentiation.

A multidimensional segmentation perspective revealing how technology types, product categories, clinical indications, distribution channels, and end users shape adoption and clinical impact

Insightful segmentation underscores how technology, product composition, clinical indication, distribution channels, and end-user profiles jointly determine product demand and adoption pathways. When the market is considered by technology, genetic testing, imaging, molecular diagnostics, and pathology each contribute distinct value propositions: imaging modalities such as CT, MRI, and PET provide structural and functional insights that guide surgical planning and monitor response; molecular diagnostics, split into next-generation sequencing and PCR approaches, deliver genomic and transcriptomic context that informs targeted therapies and clinical trial enrollment; pathology workflows encompassing biopsy analysis and histopathology remain the diagnostic anchor, integrating morphological assessment with ancillary molecular data.

Viewed through the lens of product types, consumables and reagents including kits and probes enable much of the molecular testing throughput, while diagnostic systems, imaging systems, and lab instruments form the capital infrastructure that dictates testing capacity and throughput. Services such as equipment maintenance, training, and technical support are critical to sustaining diagnostic quality and uptime. Considering clinical indications, diagnostic needs differ across tumor classes including astrocytoma, glioblastoma multiforme, meningioma, and oligodendroglioma; glioblastoma multiforme cases often demand rapid, multimodal diagnostics for aggressive treatment planning, whereas meningioma evaluation may rely more heavily on imaging characteristics and surgical pathology. Distribution channel dynamics reveal that offline relationships remain essential for complex installations and clinician engagement, while online channels are increasingly influential for consumables procurement and information dissemination. Finally, end-user segmentation shows divergent priorities: diagnostic laboratories emphasize throughput, validation, and compliance; hospitals prioritize integrated workflows and multidisciplinary coordination; research institutes prioritize analytical flexibility and assay development capacity. Understanding how these segments interact clarifies where innovation investments and commercial efforts will yield the strongest clinical and economic returns.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption pathways and strategic priorities for diagnostics

Regional dynamics are central to strategy because clinical practice patterns, regulatory environments, and healthcare infrastructure vary substantially across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems tend to feature advanced tertiary centers with high adoption of cutting-edge imaging and molecular diagnostics, supported by established reimbursement mechanisms and sizable research networks. This enables rapid translation of innovations into clinical pathways but also creates competitive pressure for differentiated diagnostics that demonstrate clear clinical utility.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous reimbursement environments prompt vendors to pursue country-level strategies, often partnering with regional distributors and academic centers to validate clinical and economic value. Meanwhile, Asia-Pacific presents a mix of high-growth urban health systems and resource-constrained settings; large academic hospitals and research institutes in major markets drive adoption of NGS and advanced imaging, while other areas prioritize cost-effective, scalable diagnostics and robust supply chain solutions. Across these regions, the interplay between local clinical practice, infrastructure readiness, and commercial models dictates where manufacturers should prioritize investments in training, service networks, and evidence generation to support uptake.

Competitive landscape dynamics revealing how incumbents, specialized molecular firms, and agile innovators are positioning through partnerships, evidence, and service offerings

Competitive landscapes in brain cancer diagnostics are characterized by a mix of established imaging and laboratory instrument manufacturers, specialized molecular diagnostics firms, and emerging players focused on AI-driven interpretation or novel assay chemistries. Incumbent imaging vendors maintain strong relationships with hospitals and neurosurgical centers through bundled service agreements and long-term maintenance contracts, which creates high switching costs but also opens opportunities for partnerships on hybrid imaging and workflow integration. Molecular diagnostics companies differentiate through panel breadth, assay sensitivity, and validation against clinical endpoints, often collaborating with academic centers for prospective evaluation and guideline inclusion.

Smaller innovators are carving niche positions with single-analyte tests or AI algorithms that augment radiological and pathological interpretation, and they often seek co-development or licensing agreements with larger manufacturers to scale distribution. Across the competitive spectrum, companies that align their offerings with clinician workflows, provide robust real-world evidence, and support implementation through training and service are most likely to secure sustained adoption. Strategic alliances, technology licensing, and targeted acquisitions remain the primary routes by which market participants expand capabilities and geographic reach.

Actionable strategic priorities for industry leaders to align product innovation, supply chain resilience, and evidence generation with clinical adoption imperatives

Industry leaders should pursue a three-pronged approach to maximize clinical impact while preserving commercial resilience: invest in integrated diagnostic solutions that combine imaging, molecular data, and pathologic context; strengthen supply chain resilience through strategic sourcing and service models; and build robust evidence generation programs that demonstrate clinical utility and economic value. Prioritizing integrated solutions reduces friction in clinical workflows and fosters deeper institutional relationships, while investment in maintenance, training, and remote support mitigates downtime risk and enhances customer retention.

In parallel, companies should adopt flexible commercial models that accommodate both centralized laboratory workflows and point-of-care testing paradigms, enabling penetration across hospital systems and specialized diagnostic laboratories. Evidence generation must include prospective clinical validation and health-economic analyses that resonate with payers and hospital procurement committees. Finally, cultivating partnerships with academic centers and patient advocacy groups accelerates access to clinical cohorts for validation and increases the likelihood of guideline adoption and clinician endorsement.

Rigorous mixed-method research approach combining primary clinician engagement and secondary literature synthesis to validate diagnostic performance and implementation insights

This analysis synthesizes primary interviews with clinical experts, laboratory directors, and industry executives, together with secondary research across peer-reviewed literature, regulatory publications, and technology white papers. Primary qualitative engagements informed perspectives on clinical workflows, pain points in diagnostic pathways, and practical constraints faced by hospitals and diagnostic laboratories. Secondary sources were used to triangulate technology capabilities, regulatory milestones, and public sector procurement trends, with particular attention to recent peer-reviewed studies that validate diagnostic performance metrics and implementation outcomes.

Data integrity was reinforced through a multi-layered validation process that included cross-verification of technological attributes with manufacturer technical specifications and consultation with independent clinical pathologists. Limitations and potential biases were addressed by sampling across geographies and facility types, and by documenting areas where empirical evidence remains nascent, such as clinical utility for certain emerging liquid biopsy approaches. Wherever possible, conclusions prioritize reproducible clinical findings and consensus viewpoints from experienced practitioners to ensure the analysis is actionable and grounded in clinical reality.

Concise synthesis emphasizing the integration of technology, evidence, and operational strategy needed to translate diagnostic advances into improved patient outcomes

In conclusion, the brain cancer diagnostics arena is transitioning toward integrated, data-rich diagnostic ecosystems that combine advanced imaging, molecular profiling, and enhanced pathology workflows. This trajectory offers meaningful opportunities to improve diagnostic precision and to personalize treatment selection, but realizing that potential requires coordinated investments in technology integration, clinician training, and evidence generation. At the same time, evolving trade dynamics and regional variations in regulatory and reimbursement environments necessitate adaptive commercial strategies and resilient supply chains.

Decision-makers should therefore focus on enabling interoperability across modalities, supporting clinical adoption with compelling real-world evidence, and designing flexible delivery models that accommodate diverse institutional needs. By aligning technological innovation with pragmatic implementation pathways and payer engagement, stakeholders can accelerate the translation of diagnostic advances into improved patient outcomes while maintaining operational and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of next generation sequencing for personalized brain tumor molecular profiling
  • 5.2. Integration of artificial intelligence algorithms in MRI analysis to improve diagnostic accuracy
  • 5.3. Development of liquid biopsy assays for noninvasive detection of glioblastoma recurrence and progression
  • 5.4. Emergence of multiplex immunoassay panels for simultaneous detection of neural protein biomarkers
  • 5.5. Expansion of telemedicine platforms for remote neuroimaging review and multidisciplinary consultation
  • 5.6. Advancements in PET tracers targeting tumor metabolism for earlier brain cancer detection and monitoring
  • 5.7. Regulatory approvals driving commercialization of point-of-care glioma diagnostic devices in clinical settings
  • 5.8. Growth of integrated diagnostic platforms combining imaging, genomics, and proteomics data for precision medicine
  • 5.9. Increasing collaboration between pharmaceutical and diagnostic firms to co-develop companion brain cancer tests
  • 5.10. Rising demand for cost-effective screening solutions in emerging markets to improve brain tumor early detection rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Diagnostics Market, by Technology

  • 8.1. Genetic Testing
  • 8.2. Imaging
    • 8.2.1. CT Scan
    • 8.2.2. MRI
    • 8.2.3. PET
  • 8.3. Molecular Diagnostics
    • 8.3.1. NGS
    • 8.3.2. PCR
  • 8.4. Pathology
    • 8.4.1. Biopsy Analysis
    • 8.4.2. Histopathology

9. Brain Cancer Diagnostics Market, by Product

  • 9.1. Consumables & Reagents
    • 9.1.1. Kits
    • 9.1.2. Probes & Reagents
  • 9.2. Equipment
    • 9.2.1. Diagnostic Systems
    • 9.2.2. Imaging Systems
    • 9.2.3. Lab Instruments
  • 9.3. Services
    • 9.3.1. Maintenance
    • 9.3.2. Training & Support

10. Brain Cancer Diagnostics Market, by Indication

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma Multiforme
  • 10.3. Meningioma
  • 10.4. Oligodendroglioma

11. Brain Cancer Diagnostics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Brain Cancer Diagnostics Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Brain Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. General Electric Company
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Koninklijke Philips N.V.
    • 16.3.4. Canon Medical Systems Corporation
    • 16.3.5. F. Hoffmann-La Roche Ltd.
    • 16.3.6. Thermo Fisher Scientific Inc.
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. Illumina, Inc.
    • 16.3.9. Abbott Laboratories
    • 16.3.10. Agilent Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS,